To evaluate MDM2 and MDMX expression with EMT in clinical cancer samples, we analyzed archived formalin-fixed paraffin-embedded tissue specimens from a cohort of prostate cancer (CaP) and breast cancer (BrCa) patients who underwent surgical resection of the primary tumor and its lymph node (LN) metastases. Here, MDM2 is linked to prostate cancer.